PL433946A1 - Test diagnostyczny wczesnego wykrywania raków u kobiet oparty o ocenę stężeń arsenu we krwi i wybranych genotypów - Google Patents

Test diagnostyczny wczesnego wykrywania raków u kobiet oparty o ocenę stężeń arsenu we krwi i wybranych genotypów

Info

Publication number
PL433946A1
PL433946A1 PL433946A PL43394620A PL433946A1 PL 433946 A1 PL433946 A1 PL 433946A1 PL 433946 A PL433946 A PL 433946A PL 43394620 A PL43394620 A PL 43394620A PL 433946 A1 PL433946 A1 PL 433946A1
Authority
PL
Poland
Prior art keywords
blood
assessment
diagnostic test
cancer detection
early cancer
Prior art date
Application number
PL433946A
Other languages
English (en)
Inventor
Jan Lubiński
Cezary Cybulski
Jacek Gronwald
Tomasz Huzarski
Katarzyna Białkowska
Róża Derkacz
Wojciech MARCINIAK
Anna Jakubowska
Original Assignee
Read-Gene Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Read-Gene Spółka Akcyjna filed Critical Read-Gene Spółka Akcyjna
Priority to PL433946A priority Critical patent/PL433946A1/pl
Publication of PL433946A1 publication Critical patent/PL433946A1/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Przedmiotem zgłoszenia jest test diagnostyczny wczesnego wykrywania raków u kobiet oparty o ocenę stężeń arsenu we krwi i wybranych genotypów. Sposób określenia prawdopodobieństwa wystąpienia raka jelita grubego u kobiet, charakteryzuje się tym, że obejmuje ilościową ocenę zawartości arsenu we krwi pełnej, przy czym stężenia arsenu ≤ 0,65 µg/l wskazują na ponad 2 krotnie zwiększoną częstość występowania raka jelita grubego.
PL433946A 2020-05-14 2020-05-14 Test diagnostyczny wczesnego wykrywania raków u kobiet oparty o ocenę stężeń arsenu we krwi i wybranych genotypów PL433946A1 (pl)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL433946A PL433946A1 (pl) 2020-05-14 2020-05-14 Test diagnostyczny wczesnego wykrywania raków u kobiet oparty o ocenę stężeń arsenu we krwi i wybranych genotypów

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL433946A PL433946A1 (pl) 2020-05-14 2020-05-14 Test diagnostyczny wczesnego wykrywania raków u kobiet oparty o ocenę stężeń arsenu we krwi i wybranych genotypów

Publications (1)

Publication Number Publication Date
PL433946A1 true PL433946A1 (pl) 2021-11-15

Family

ID=78595449

Family Applications (1)

Application Number Title Priority Date Filing Date
PL433946A PL433946A1 (pl) 2020-05-14 2020-05-14 Test diagnostyczny wczesnego wykrywania raków u kobiet oparty o ocenę stężeń arsenu we krwi i wybranych genotypów

Country Status (1)

Country Link
PL (1) PL433946A1 (pl)

Similar Documents

Publication Publication Date Title
Sowa et al. Novel algorithm for non-invasive assessment of fibrosis in NAFLD
Labenz et al. Validation of the simplified Animal Naming Test as primary screening tool for the diagnosis of covert hepatic encephalopathy
Mehta et al. The utility of nodule volume in the context of malignancy prediction for small pulmonary nodules
Lekva et al. Prediction of gestational diabetes mellitus and pre-diabetes 5 years postpartum using 75 g oral glucose tolerance test at 14–16 weeks’ gestation
Sjoberg et al. Twenty-year risk of prostate cancer death by midlife prostate-specific antigen and a panel of four kallikrein markers in a large population-based cohort of healthy men
Hjiyiannakis et al. Thyroglobulin antibodies in differentiated thyroid cancer
Schneider et al. Sarcopenia and major complications in patients undergoing oncologic colon surgery
ATE536553T1 (de) Verfahren zum nachweis grösserer ungünstiger kardiovaskulärer und zerebrovaskulärer ereignisse
Li et al. Risk factors for concomitant infectious pancreatic necrosis in patients with severe acute pancreatitis: A systematic review and meta-analysis
Ismail Identifying and reducing potentially wrong immunoassay results even when plausible and “not-unreasonable”
Kowalska et al. The cut-off level of recombinant human TSH-stimulated thyroglobulin in the follow-up of patients with differentiated thyroid cancer
Verdial et al. Prediction model for nodal disease among patients with non–small cell lung cancer
Park et al. Inverse association between visceral obesity and lymph node metastasis in gastric cancer
Koca et al. Factors affecting thyroid elastography in healthy children and patients with Hashimoto’s thyroiditis
Pestana et al. Colorectal cancer: comparative analysis of clinical and pathological characteristics in patients aged above and below 45 years of age and impact on prognosis
Lidbury et al. Evaluation of hyaluronic acid, procollagen type III N-terminal peptide, and tissue inhibitor of matrix metalloproteinase-1 as serum markers of canine hepatic fibrosis
Li et al. Thyrotropin receptor antibody: A novel risk indicator for pregnancy loss
PL433946A1 (pl) Test diagnostyczny wczesnego wykrywania raków u kobiet oparty o ocenę stężeń arsenu we krwi i wybranych genotypów
Takahashi et al. Optimal cutoff points of CYFRA21-1 for survival prediction in non-small cell lung cancer patients based on running statistical analysis
Murano et al. Novel and Effective Blood‐Based miRNA Diagnostic Panel for Gastric Cancer: A Pilot Study in a Japanese Population
Masterson et al. Dental enamel defects predict adolescent health indicators: A cohort study among the Tsimane’of Bolivia
Murray et al. Limited improvement of incorporating primary circulating prostate cells with the CAPRA score to predict biochemical failure-free outcome of radical prostatectomy for prostate cancer
Seikkula et al. Role of ultrasensitive prostate-specific antigen in the follow-up of prostate cancer after radical prostatectomy
Suresh et al. A comparative study of RIPASA and Alvarado score for the diagnosis of acute appendicitis
ES2325170T3 (es) Un metodo para predecir el estado de la mucosa gastrica.